Cargando…
Hydralazine target: From blood vessels to the epigenome
Hydralazine was one of the first orally active antihypertensive drugs developed. Currently, it is used principally to treat pregnancy-associated hypertension. Hydralazine causes two types of side effects. The first type is an extension of the pharmacologic effect of the drug and includes headache, n...
Autores principales: | Arce, Claudia, Segura-Pacheco, Blanca, Perez-Cardenas, Enrique, Taja-Chayeb, Lucia, Candelaria, Myrna, Dueñnas-Gonzalez, Alfonso |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1413557/ https://www.ncbi.nlm.nih.gov/pubmed/16507100 http://dx.doi.org/10.1186/1479-5876-4-10 |
Ejemplares similares
-
Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines
por: Chavez-Blanco, Alma, et al.
Publicado: (2006) -
Global DNA hypermethylation-associated cancer chemotherapy resistance and its reversion with the demethylating agent hydralazine
por: Segura-Pacheco, Blanca, et al.
Publicado: (2006) -
DNA Methylation-Independent Reversion of Gemcitabine Resistance by Hydralazine in Cervical Cancer Cells
por: Candelaria, Myrna, et al.
Publicado: (2012) -
A phase I study of hydralazine to demethylate and reactivate the expression of tumor suppressor genes
por: Zambrano, Pilar, et al.
Publicado: (2005) -
Epigenetic therapy with hydralazine and valproate associated to cisplatin chemoradiation in FIGO stage IIIB. A phase II study
por: Candelaria, Myrna, et al.
Publicado: (2007)